ENYO Pharma has decided to open its first wholly owned subsidiary in Melbourne, Australia, because of its clinical trials development capabilities and conditions offered by the government. The Australian Government is supportive of biotech startups and the Victorian Government Business Office provides good business development networking. This office will be the new ENYO Pharma center to manage EYP001 (an FXR agonist) clinical trials in the Asia-Pacific region for chronic Hepatitis B. A Phase 1b study of EYP001 is currently submitted in 4 countries and two new Australian centers in Sydney and Perth have joined the study and started recruitment.
ENYO Pharma bases its innovation on mimicking viral strategies to discover new cellular targets and is currently developing drug candidates in therapeutic areas such as infectious and metabolic diseases. One of the company’s leading programs is a new drug EYP001, against chronic Hepatitis B which is a major public health concern in the Asia-Pacific region. More than a half of the global population infected worldwide by Hepatitis B are located in this region, representing 129 million patients.
“ENYO Pharma is currently looking forward to working in this region as the well-established clinical expertise in this part of the world adds important value to ENYO Pharma R&D efforts and specifically our expeditious development of EYP001” Pietro Scalfaro, M.D., Chief Medical Officer of ENYO Pharma SA said.